【招银国际证券】 Eyes on next steps of orelabrutinib for MS.pdf

Biogen returned global rights of Orelabrutinib

–Consistent results of orelabrutinib for MS

Breakup with Biogen on orelabrutinib for the treatment of autoimmune diseases